| 000 | 01903 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250513232723.0 | ||
| 264 | 0 | _c20010329 | |
| 008 | 200103s 0 0 eng d | ||
| 022 | _a0732-183X | ||
| 024 | 7 |
_a10.1200/JCO.2001.19.5.1248 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDelaloge, S | |
| 245 | 0 | 0 |
_aEcteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity. _h[electronic resource] |
| 260 |
_bJournal of clinical oncology : official journal of the American Society of Clinical Oncology _cMar 2001 |
||
| 300 |
_a1248-55 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Alkylating _xadverse effects |
| 650 | 0 | 4 |
_aBone Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aDioxoles _xadverse effects |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIsoquinolines _xadverse effects |
| 650 | 0 | 4 |
_aLiver _xdrug effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeutropenia _xchemically induced |
| 650 | 0 | 4 |
_aSarcoma _xdrug therapy |
| 650 | 0 | 4 | _aTetrahydroisoquinolines |
| 650 | 0 | 4 | _aTrabectedin |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aYovine, A | |
| 700 | 1 | _aTaamma, A | |
| 700 | 1 | _aRiofrio, M | |
| 700 | 1 | _aBrain, E | |
| 700 | 1 | _aRaymond, E | |
| 700 | 1 | _aCottu, P | |
| 700 | 1 | _aGoldwasser, F | |
| 700 | 1 | _aJimeno, J | |
| 700 | 1 | _aMisset, J L | |
| 700 | 1 | _aMarty, M | |
| 700 | 1 | _aCvitkovic, E | |
| 773 | 0 |
_tJournal of clinical oncology : official journal of the American Society of Clinical Oncology _gvol. 19 _gno. 5 _gp. 1248-55 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1200/JCO.2001.19.5.1248 _zAvailable from publisher's website |
| 999 |
_c11167968 _d11167968 |
||